Newly Launched Trastuzumab Biosimilars Trigger Price Cuts In India
This article was originally published in The Pink Sheet Daily
Executive Summary
Even as litigation shadows opportunities for trastuzumab biosimilars in India, dealers noted that discounted prices are being offered across the board. The four-way rivalry with Biocon and Mylan on one side and Roche and Emcure on the other has already intensified market competition, experts say.
You may also be interested in...
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.
Could Indian heart stent study findings lead to price cuts?
India’s top regulatory agencies are weighing up the findings from a study it had commissioned that looks at the clinical benefits of heart stents, with the possible aim of using the results to back the use of cheaper, locally-produced devices.